2004-000755-41: A three-month, double-blind, double dummy, parallel group, controlled study comparing the efficacy and safety between 12 µg twice daily of Formoterol-HFA and 12 µg twice daily of Formoterol-DPI (Foradil/Aerolizer) in children with persistent asthma |
|
|
| Ongoing | 3 | 34 | Europe | Formoterol Fumarate, Foradil 12µg poudre pour inhalation, CHF 1531, Atismos 12µg pressurised inhalation solution 120 actuations, Foradil 12µg proudre pour inhalation, Atismos 12µg pressurised inhalation solution 120 actuations, Foradil 12µg proudre pour inhalation | Chiesi Farmaceurtici S.p.A | Children Persistent Asthma | | | | |
2005-003826-24: A RANDOMISED, FOUR WAY CROSS-OVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW GENERIC DRY POWDER FORMOTEROL FORMULATION GIVEN AS CUMULATIVE DOSES FROM A NOVEL DRY POWDER INHALER AND TWO REFERENCE DRY POWDER FORMULATIONS IN ADULT ASTHMATIC PATIENTS |
|
|
| Ongoing | 3 | 32 | Europe | formoterol, MIAT HALER, Foradil Aerolizer, Oxis Turbohaler, Foradil Aerolizer, Oxis Turbohaler | Andi - Ventis | reversible mild asthma | | | | |
2005-002538-37: Randomised, double-blind study to demonstrate therapeutic equivalence of formoterol fumarate 12µg capsules delivered by Cyclohaler with Foradil in mild to moderate reversible obstructive airways disease. |
|
|
| Ongoing | 2 | 30 | Europe | Formoterol 12 mcg capsules, Foradil Aerolizer, Foradil, Foradil | Pharmachemie B.V. | mild to moderate reversible obstructive airways disease | | | | |